adding to targeted therapy: current statistics and biology - targeted therapies in lung cancer 2023
Published 1 year ago • 64 plays • Length 4:57Download video MP4
Download video MP3
Similar videos
-
5:17
adding to targeted therapy: current statistics and biology
-
9:06
advocacy resources and organizations to know - targeted therapies in lung cancer 2023
-
4:04
challenges of targeted kras treatment & current treatments - targeted therapies in lung cancer 2023
-
2:36
the future of local therapy - targeted therapies in lung cancer 2023
-
4:48
biomarker driven therapy for nsclc - targeted therapies in lung cancer 2023
-
16:51
an introduction to advocacy - targeted therapies in lung cancer 2023
-
3:02
the future of ret nsclc treatment - targeted therapies in lung cancer 2023
-
58:19
the implications of recent datasets for the current and future management of nsclc egfr mutations
-
4:40
tki neoadjuvant: is complete pathological response possible?- targeted therapies in lung cancer 2023
-
5:31
biomarkers in nsclc - targeted therapies in lung cancer 2023
-
3:02
resistance mechanisms in egfr nsclc treatment - targeted therapies in lung cancer 2023
-
6:06
the adaura trial: the effect on egfr treatment - targeted therapies in lung cancer 2023
-
2:00
why some patients remain on tkis without acquiring resistance? - targeted therapies in lung cancer
-
3:58
local therapy for limited metastatic nsclc - targeted therapies in lung cancer 2023
-
4:37
targeted therapy in lung cancer: the importance of biomarkers - lcvl 2024
-
3:33
current recommendations and best practices for biomarker testing - targeted therapies in lung cancer
-
2:43
nrg1 fusions: treatment options - targeted therapies in lung cancer 2023
-
6:04
resistance on targeted therapy: questions patients should ask-targeted therapies in lung cancer 2023
-
1:36
q&a: does braf in non-smokers respond to immunotherapy? - targeted therapies in lung cancer 2023